Internal Medicine, Endocrinology, Diabetes, & Metabolism · New York, NY
NPI
1346774015
Since 2017
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
222 E 41st St
New York, NY, 10017
Phone (212) 481-1350
Groups this clinician bills Medicare through
Medicare paid, 2024
$66K
969 services
Medicare patients, 2024
253
Average age 74
Drug cost, 2024
$2.0M
1,573 prescriptions
Company payments, 2024
$411
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Weintraub was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 268 times for 177 patients. In total Michael Weintraub billed 969 services in 17 codes, and Medicare paid $66K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-02.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 268 | 177 | $13.81 | $3,702 |
| 99215 Office E&M - Established | Office | 218 | 144 | $142.16 | $31K |
| 99214 Office E&M - Established | Office | 193 | 139 | $105.17 | $20K |
| 82962 Clinical Chemistry | Office | 84 | 46 | $3.21 | $270 |
| 36415 Venipuncture Blood Collection | Office | 82 | 66 | $8.65 | $709 |
| 95251 Test - Miscellaneous | Office | 39 | 19 | $27.97 | $1,091 |
| 99204 Office E&M - New | Office | 25 | 25 | $129.72 | $3,243 |
| 99205 Office E&M - New | Office | 23 | 23 | $186.27 | $4,284 |
By year: 2022 $8,850 for 77 services; 2023 $58K for 561 services; 2024 $66K for 969 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 84 | 46 | $3.21 | $270 |
| 36415 Venipuncture Blood Collection | 82 | 66 | $8.65 | $709 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael Weintraub prescribed most often to Medicare patients was Levothyroxine Sodium, with 184 prescriptions and refills. In total Michael Weintraub wrote 1,573 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 184 | 483 | 59 | $2,572 |
| Metformin Hcl Er Metformin Hcl | 149 | 410 | 54 | $2,810 |
| Mounjaro Tirzepatide | 138 | 213 | 29 | $218K |
| Synthroid Levothyroxine Sodium | 123 | 347 | 38 | $13K |
| Ozempic Semaglutide | 119 | 227 | 32 | $217K |
| Jardiance Empagliflozin | 93 | 230 | 27 | $128K |
| Metformin Hcl Generic | 55 | 163 | 23 | $563 |
| Januvia Sitagliptin Phosphate | 40 | 64 | Under 11 | $33K |
| Atorvastatin Calcium Generic | 38 | 114 | 12 | $406 |
| Hydrocortisone Generic | 37 | 59 | Under 11 | $1,239 |
| Trulicity Dulaglutide | 30 | 35 | Under 11 | $31K |
| Ezetimibe Generic | 26 | 45 | Under 11 | $252 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 25 | 41 | 11 | $1,980 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 25 | 35 | Under 11 | $1,586 |
| Humalog Kwikpen U-100 Insulin Lispro | 20 | 25 | Under 11 | $2,816 |
Brand drugs: 804 claims; generic drugs: 675 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Michael Weintraub $411 ($411 in general payments such as food, travel and fees) from 3 companies. The largest payer was Novo Nordisk Inc with $175.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.